Health Catalyst (HCAT) Expected to Announce Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Health Catalyst to post earnings of $0.11 per share and revenue of $79.59 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Health Catalyst Trading Down 0.4 %

HCAT opened at $5.40 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $328.59 million, a PE ratio of -4.00 and a beta of 1.34. Health Catalyst has a 1-year low of $5.32 and a 1-year high of $9.89. The firm has a 50-day moving average price of $6.41 and a two-hundred day moving average price of $7.32.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company lowered their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Stephens raised their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Piper Sandler reduced their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and an average price target of $10.20.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84. Following the completion of the transaction, the chief operating officer now owns 86,044 shares in the company, valued at approximately $495,613.44. The trade was a 5.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the transaction, the chief financial officer now owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. This represents a 18.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,169 shares of company stock worth $629,068. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.